Skip to Main Content
DownloadHi-Res Photo

Brett King, MD, PhD

Associate Professor of Dermatology

Contact Information

Brett King, MD, PhD

Mailing Address

  • Dermatology

    1625 Straits Turnpike, Suite 211

    Middlebury, CT 06762

    United States

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Coauthors

Research Interests

Alopecia Areata; Eczema; Stevens-Johnson Syndrome; Vitiligo; Scleroderma, Limited

Selected Publications

  • Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2020, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.
  • Treatment of granuloma annulare with tofacitinib 2% ointment.Damsky W, King BA. Treatment of granuloma annulare with tofacitinib 2% ointment. JAAD Case Reports 2020, 6: 69-71. PMID: 31909145, PMCID: PMC6940619, DOI: 10.1016/j.jdcr.2019.10.016.
  • Treatment of Multiorgan Sarcoidosis With Tofacitinib.Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatology 2020, 2: 106-109. PMID: 31916703, PMCID: PMC7011417, DOI: 10.1002/acr2.11112.
  • Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea.Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea. The Journal Of Investigative Dermatology 2020, 140: 1446-1449.e4. PMID: 31954727, DOI: 10.1016/j.jid.2019.12.019.
  • Treatment of severe lichen planus with the JAK inhibitor tofacitinib.Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. The Journal Of Allergy And Clinical Immunology 2020, 145: 1708-1710.e2. PMID: 32018031, DOI: 10.1016/j.jaci.2020.01.031.
  • Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid.Damsky W, Singh K, Galan A, King B. Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid. JAAD Case Reports 2020, 6: 133-135. PMID: 32021895, PMCID: PMC6994271, DOI: 10.1016/j.jdcr.2019.11.016.
  • The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Peterson D, Damsky W, King B. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Journal Of The American Academy Of Dermatology 2020, 82: e223-e226. PMID: 32278797, PMCID: PMC7144601, DOI: 10.1016/j.jaad.2020.03.099.
  • The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata.Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, Bergfeld WF, Betz RC, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Donovan J, Eisman S, Farrant P, Green J, Grimalt R, Harries M, Hordinsky M, Irvine AD, Itami S, Jolliffe V, King B, Lee WS, McMichael A, Messenger A, Mirmirani P, Olsen E, Orlow SJ, Piraccini BM, Rakowska A, Reygagne P, Roberts JL, Rudnicka L, Shapiro J, Sharma P, Tosti A, Vogt A, Wade M, Yip L, Zlotogorski A, Sinclair R. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. Journal Of The American Academy Of Dermatology 2020, 83: 123-130. PMID: 32165196, DOI: 10.1016/j.jaad.2020.03.004.
  • Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, Gordon S, Ahmed R, Nichols A, Rothe M, Rosmarin D. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. Journal Of The American Academy Of Dermatology 2020, 83: 46-52. PMID: 32179082, DOI: 10.1016/j.jaad.2020.01.089.
  • The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature.Wang A, Singh K, Ibrahim W, King B, Damsky W. The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature. The Yale Journal Of Biology And Medicine 2020, 93: 187-195. PMID: 32226347, PMCID: PMC7087061.
  • Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.Peterson D, Damsky W, King B. Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19. Journal Of The American Academy Of Dermatology 2020, 83: e67-e68. PMID: 32344070, PMCID: PMC7194643, DOI: 10.1016/j.jaad.2020.04.097.
  • Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata.Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. American Journal Of Clinical Dermatology 2020, 21: 725-732. PMID: 32803546, PMCID: PMC7473969, DOI: 10.1007/s40257-020-00545-9.
  • Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity?Peterson D, King B. Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity? Journal Of The American Academy Of Dermatology 2021, 84: e63-e64. PMID: 32891783, DOI: 10.1016/j.jaad.2020.08.120.
  • "'You lose your hair, what's the big deal?' I was so embarrassed, I was so self-conscious, I was so depressed:" a qualitative interview study to understand the psychosocial burden of alopecia areata.Aldhouse NVJ, Kitchen H, Knight S, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA, Wyrwich KW. "'You lose your hair, what's the big deal?' I was so embarrassed, I was so self-conscious, I was so depressed:" a qualitative interview study to understand the psychosocial burden of alopecia areata. Journal Of Patient-reported Outcomes 2020, 4: 76. PMID: 32914253, PMCID: PMC7483696, DOI: 10.1186/s41687-020-00240-7.
  • Tofacitinib for the treatment of alopecia areata in preadolescent children.Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. Journal Of The American Academy Of Dermatology 2019, 80: 568-570. PMID: 30195571, DOI: 10.1016/j.jaad.2018.08.041.
  • Ruxolitinib for the treatment of severe alopecia areata.Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. Journal Of The American Academy Of Dermatology 2019, 80: 566-568. PMID: 30195572, DOI: 10.1016/j.jaad.2018.08.040.
  • Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies-Taming T REX.Damsky W, King BA. Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies-Taming T REX. JAMA Dermatology 2019, 155: 283-284. PMID: 30673073, DOI: 10.1001/jamadermatol.2018.4836.
  • Rethinking the classification of alopecia areata.Wambier CG, King BA. Rethinking the classification of alopecia areata. Journal Of The American Academy Of Dermatology 2019, 80: e45. PMID: 30244065, DOI: 10.1016/j.jaad.2018.08.059.
  • Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata.Liu LY, King BA. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. Journal Of The American Academy Of Dermatology 2019, 80: 1778-1779. PMID: 30502414, DOI: 10.1016/j.jaad.2018.11.037.
  • Rule of thumb: A simple tool to estimate 1% scalp surface area.Wambier CG, King BA. Rule of thumb: A simple tool to estimate 1% scalp surface area. Journal Of The American Academy Of Dermatology 2019, 81: 630-631. PMID: 30682394, DOI: 10.1016/j.jaad.2019.01.022.
  • IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans.Ortolan LS, Kim SR, Crotts S, Liu LY, Craiglow BG, Wambier C, Paschoal RS, King BA, Jabbari A. IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. The Journal Of Allergy And Clinical Immunology 2019, 144: 1731-1734.e1. PMID: 31470035, PMCID: PMC6900443, DOI: 10.1016/j.jaci.2019.08.014.
  • Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. Journal Of The American Academy Of Dermatology 2021, 85: 743-745. PMID: 31499158, DOI: 10.1016/j.jaad.2019.08.080.
  • Reply to: "Comment on 'Rule of thumb: A simple tool to estimate 1% scalp surface area': Whose thumb is it anyway?"Wambier CG, King BA. Reply to: "Comment on 'Rule of thumb: A simple tool to estimate 1% scalp surface area': Whose thumb is it anyway?" Journal Of The American Academy Of Dermatology 2019, 81: e185. PMID: 31470070, DOI: 10.1016/j.jaad.2019.08.051.
  • Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib.Damsky WE, Vesely MD, Lee AI, Choi J, Meyer AC, Chen M, Ahmad T, King B. Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Reports 2019, 5: 1018-1026. PMID: 31763425, PMCID: PMC6864390, DOI: 10.1016/j.jdcr.2019.07.004.
  • Treatment of severe alopecia areata with baricitinib.Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. JAAD Case Reports 2019, 5: 892-894. PMID: 31681829, PMCID: PMC6818396, DOI: 10.1016/j.jdcr.2019.07.005.
  • Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life.Liu LY, Craiglow BG, King BA. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. Journal Of The American Academy Of Dermatology 2018, 78: 597-599.e2. PMID: 29128459, DOI: 10.1016/j.jaad.2017.10.046.
  • Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families.Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families. Journal Of The American Academy Of Dermatology 2018, 79: 556-558.e1. PMID: 29425723, DOI: 10.1016/j.jaad.2018.01.048.
  • Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. Journal Of The American Academy Of Dermatology 2018, 78: 403-404.e1. PMID: 29108908, DOI: 10.1016/j.jaad.2017.10.043.
  • Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.Kim SR, Heaton H, Liu LY, King BA. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. JAMA Dermatology 2018, 154: 370-371. PMID: 29387870, DOI: 10.1001/jamadermatol.2017.5778.
  • Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Reports 2018, 4: 443-445. PMID: 29984277, PMCID: PMC6031588, DOI: 10.1016/j.jdcr.2017.12.003.
  • Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. The New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/NEJMoa1805958.
  • Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management.Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management. JAMA Dermatology 2018, 154: 1485-1486. PMID: 30347029, DOI: 10.1001/jamadermatol.2018.3427.
  • JAK inhibitors in dermatology: The promise of a new drug class.Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal Of The American Academy Of Dermatology 2017, 76: 736-744. PMID: 28139263, PMCID: PMC6035868, DOI: 10.1016/j.jaad.2016.12.005.
  • Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis.Vesely MD, Imaeda S, King BA. Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis. JAAD Case Reports 2017, 3: 4-6. PMID: 28050588, PMCID: PMC5192094, DOI: 10.1016/j.jdcr.2016.09.008.
  • Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Journal Of The American Academy Of Dermatology 2017, 77: 675-682.e1. PMID: 28823882, PMCID: PMC6233876, DOI: 10.1016/j.jaad.2017.05.043.
  • Tofacitinib for the treatment of alopecia areata and variants in adolescents.Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. Journal Of The American Academy Of Dermatology 2017, 76: 29-32. PMID: 27816292, DOI: 10.1016/j.jaad.2016.09.006.
  • Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.King B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. The Journal Of Investigative Dermatology 2017, 137: 951-954. PMID: 27887955, PMCID: PMC5387413, DOI: 10.1016/j.jid.2016.10.044.
  • Lack of efficacy of apremilast in 9 patients with severe alopecia areata.Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. Journal Of The American Academy Of Dermatology 2017, 77: 773-774. PMID: 28917463, DOI: 10.1016/j.jaad.2017.05.034.
  • Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. Journal Of The American Academy Of Dermatology 2017, 76: 22-28. PMID: 27816293, DOI: 10.1016/j.jaad.2016.09.007.
  • Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome.Walker S, Wang C, Walradt T, Hong BS, Tanner JR, Levinsohn JL, Goh G, Subtil A, Lessin SR, Heymann WR, Vonderheid EC, King BA, Lifton RP, Choi J. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood 2016, 127: 948-51. PMID: 26702067, PMCID: PMC4760095, DOI: 10.1182/blood-2015-06-654277.
  • Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis.Dhayalan A, King BA. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis. JAMA Dermatology 2016, 152: 492-3. PMID: 26630079, DOI: 10.1001/jamadermatol.2015.3772.
  • Topical Ruxolitinib for the Treatment of Alopecia Universalis.Craiglow BG, Tavares D, King BA. Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatology 2016, 152: 490-1. PMID: 26649829, DOI: 10.1001/jamadermatol.2015.4445.
  • Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC, Marinkovich MP, Christiano AM, Oro AE, King BA. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 2016, 1: e89776. PMID: 27699252, PMCID: PMC5033755, DOI: 10.1172/jci.insight.89776.
  • STATing the obvious: it's time for new treatments in atopic dermatitis.Damsky W, King BA. STATing the obvious: it's time for new treatments in atopic dermatitis. The British Journal Of Dermatology 2016, 175: 861-862. PMID: 27790697, DOI: 10.1111/bjd.15036.
  • Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review.Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. Journal Of The American Academy Of Dermatology 2016, 75: 806-812.e3. PMID: 27436156, DOI: 10.1016/j.jaad.2016.04.035.
  • Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. Journal Of The American Academy Of Dermatology 2015, 73: 395-9. PMID: 26194706, DOI: 10.1016/j.jaad.2015.06.045.
  • Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatology 2015, 151: 1110-2. PMID: 26107994, DOI: 10.1001/jamadermatol.2015.1520.
  • Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. The Journal Of Investigative Dermatology 2014, 134: 2988-2990. PMID: 24940651, DOI: 10.1038/jid.2014.260.
Edit Profile